论文部分内容阅读
本会议于1992年3月在法国召开.其目的是突出欧洲在向世界提供高质量疫苗方面过去和现在所起的重要作用.目前欧洲的制造厂向全世界提供了WHO扩大免疫计划(EPI)中所用疫苗的2/3.未来的目标是开发预防目前在世界发病和死亡中仍起显著作用的疾病.参加本会议的有来自60多个国家的代表以及WHO、联合国其他组织和欧洲共同体的有关人员.第一分会的主题是当前欧洲的贡献,讨论欧洲疫苗生产者通过改进产品和试验步骤来达到符合WHO的质量保证规定.如生产安全有效的细胞培养狂犬病疫苗和用重组DNA技术生产的乙肝疫苗,希望将乙肝疫苗纳入白喉、破伤风和百日咳联合疫苗中.第二分会检查了新疫苗的前景和改进;报告了预防腹泻和寄生虫病的安全
The conference was held in France in March 1992. Its purpose is to highlight the important role played by Europe in the past and present in the delivery of high-quality vaccines to the world, which now offers the World’s Enlarged Immunization Program (EPI) Of the vaccine used in the future is to develop a disease that is still playing a significant role in the morbidity and mortality in the world, with representatives from more than 60 countries and representatives from WHO, other United Nations organizations and the European Community The first chapter’s theme is the current European contribution to discussing European vaccine producers to meet WHO quality assurance requirements by improving products and testing procedures such as producing safe and effective cell culture rabies vaccines and using recombinant DNA technology Hepatitis B vaccine, hoping to include hepatitis B vaccine in a combination vaccine against diphtheria, tetanus and pertussis The second chapter examined the prospects and improvements of the new vaccine; reported safety in the prevention of diarrhea and parasites